The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue
Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy …

Diagnosis of dementia with Lewy bodies (DLB) is challenging and specific biofluid
biomarkers are highly needed. We employed proximity extension-based assays to measure …

Background Diagnosis of dementia with Lewy bodies (DLB) is challenging, largely due to a
lack of diagnostic tools. Cerebrospinal fluid (CSF) biomarkers have been proven useful in …

Parkinson's disease (PD) and Dementia with Lewy bodies (DLB) are progressive and
disabling neurodegenerative disorders, in which signs and symptoms overlap with each …

Introduction We sought to determine if a proteomic profile approach developed to detect
Alzheimer's disease would distinguish patients with Lewy body disease from normal …

Background Mixed evidence supports blood-brain barrier (BBB) dysfunction in Lewy body
spectrum diseases. Methods We compare biofluid markers in people with idiopathic …

Rationale Frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB) are two
common forms of neurodegenerative dementia, subsequent to Alzheimer's disease (AD). AD …

Highlights•Protein biomarkers in cerebrospinal fluid now define Alzheimer's disease
(AD).•New ultrasensitive techniques have enabled promising replication in blood.•This …

Background: Concomitant Alzheimer's disease (AD) pathology is observed in Lewy body
diseases (LBD), but the clinical impact is unknown. Only a few biomarker studies in LBD …

Background Currently there are no effective treatments for many neurodegenerative
diseases. Reliable biomarkers for identifying and stratifying these diseases will be important …